ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00925301
Recruitment Status : Completed
First Posted : June 22, 2009
Last Update Posted : May 2, 2016
Sponsor:
Information provided by (Responsible Party):
Amicus Therapeutics

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Actual Primary Completion Date : July 2012
  Actual Study Completion Date : January 2014
  Certification/Extension First Submitted : September 25, 2013

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 August 10, 2018
September 6, 2018
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):